644.66MMarket Cap-6103P/E (TTM)
0.000High0.000Low0Volume6.470Open6.470Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)99.64MShares6.47052wk High0.07P/B464.75MFloat Cap6.47052wk Low--Dividend TTM71.83MShs Float12.500Historical High--Div YieldTTM0.00%Amplitude0.750Historical Low--Avg Price1Lot Size
Sinovac Biotech Stock Forum
$Sinovac Biotech(SVA.US)$ $FOSUN PHARMA(02196.HK)$ $Shanghai Fosun Pharmaceutical(600196.SH)$ $CanSino Biologics Inc.(688185.SH)$ $CANSINOBIO(06185.HK)$ $Walvax Biotechnology(300142.SZ)$ $Chongqing Zhifei Biological Products(300122.SZ)$
We now know so called 90%+ effecacy rates in phase 3 tests for many vaccines are really ..., you know. They were conducted under special controls, for instance, exclude risky people, etc. Furthermore, mask mandate, etc. policies expanded their "effecacy" - actually accumulative effecacy - should be vaccine + mask, etc.
For $BioNTech(BNTX.US)$/ $Pfizer(PFE.US)$, $Moderna(MRNA.US)$, $AstraZeneca(AZN.US)$, $SINOPHARM(01099.HK)$, $Sinovac Biotech(SVA.US)$ (trade suspended), at least, we have lots of field data on safety and real effecacy. Unless you are corrupted health officials own lots of NVAX shares, how dare you introduce NVAX to replace known ones?
Not to mention, NVAX still has not given a plausible explanation of their low effecacy in phase 2b test conducted in South Africa. Rather, NVAX left (should we say "flee"?) S. Africa and conducted phase 3 in US and Mexico.
Not just in US and Europe, even in China, you can see several late comers, despite claim better than in-use HK:1099 and SVA (trade supspended), they got little business.
I doubt Chinese government want SVA resume trade in Nasdaq because the company now worth a lot. As I read, in volume, SAV has sold most vaccines, BNTX/PFE cam second, and 099 third.
By the way, 1099 does show good safety, much better than BNTX/PFE: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473339/
Will 3rd, even 4th dose manditory?
Well, good news for BNTX and MRNA but only short term boost for $Novavax(NVAX.US)$ since market has matured. PFE/BNTX and MRNA have no production capacity issue now. There can produce as many as their addressable markets want.
Of course, there are no production issues for $SINOPHARM(01099.HK)$ and $Sinovac Biotech(SVA.US)$ (trade suspended). No, NVAX cannot capture noticeable markets from them.
Helping people to overcome these fears is the only way to end this pandemic.
$Pfizer(PFE.US)$ $Sinovac Biotech(SVA.US)$ $AstraZeneca(AZN.US)$
$Sinovac Biotech(SVA.US)$
No comment yet